Cargando…

Preclinical Antimalarial Combination Study of M5717, a Plasmodium falciparum Elongation Factor 2 Inhibitor, and Pyronaridine, a Hemozoin Formation Inhibitor

Antimalarial drug resistance in the Plasmodium falciparum parasite poses a constant challenge for drug development. To mitigate this risk, new antimalarial medicines should be developed as fixed-dose combinations. Assessing the pharmacodynamic interactions of potential antimalarial drug combination...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rottmann, Matthias, Jonat, Brian, Gumpp, Christin, Dhingra, Satish K., Giddins, Marla J., Yin, Xiaoyan, Badolo, Lassina, Greco, Beatrice, Fidock, David A., Oeuvray, Claude, Spangenberg, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2020
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179297/ https://www.ncbi.nlm.nih.gov/pubmed/32041711 http://dx.doi.org/10.1128/AAC.02181-19

Ejemplares similares

Translation of liver stage activity of M5717, a Plasmodium elongation factor 2 inhibitor: from bench to bedside
por: Khandelwal, Akash, et al.
Publicado: (2022)

Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study
por: McCarthy, James S, et al.
Publicado: (2021)

Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment
por: Radohery, Georges F. R., et al.
Publicado: (2022)

In Vitro Antimalarial Activity of Inhibitors of the Human GTPase Rac1
por: Parapini, Silvia, et al.
Publicado: (2022)

Evidence for in vitro and in vivo activity of the antimalarial pyronaridine against Schistosoma
por: Koehne, Erik, et al.
Publicado: (2021)

Environmentally Responsible and Cost-Effective Synthesis of the Antimalarial Drug Pyronaridine
por: Kincaid, Joseph R. A., et al.
Publicado: (2022)

Repurposing Antimalarial Pyronaridine as a DNA Repair Inhibitor to Exploit the Full Potential of Gold-Nanoparticle-Mediated Radiation Response
por: Jackson, Nolan, et al.
Publicado: (2022)

A Novel Way to Grow Hemozoin-Like Crystals In Vitro and Its Use to Screen for Hemozoin Inhibiting Antimalarial Compounds
por: Thomas, Vincent, et al.
Publicado: (2012)

Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection
por: Lane, Thomas R., et al.
Publicado: (2019)

Correction: Evidence for in vitro and in vivo activity of the antimalarial pyronaridine against Schistosoma
por: Koehne, Erik, et al.
Publicado: (2022)

Bazedoxifene, a Postmenopausal Drug, Acts as an Antimalarial and Inhibits Hemozoin Formation
por: Sudhakar, Renu, et al.
Publicado: (2022)

Pre-erythrocytic Activity of M5717 in Monotherapy and Combination in Preclinical Plasmodium Infection Models
por: Fontinha, Diana, et al.
Publicado: (2022)

Hemozoin Promotes Lung Inflammation via Host Epithelial Activation
por: Shah, Shivang S., et al.
Publicado: (2021)

The delayed bloodstream clearance of Plasmodium falciparum parasites after M5717 treatment is attributable to the inability to modify their red blood cell hosts
por: Parkyn Schneider, Molly, et al.
Publicado: (2023)

Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers
por: Sinxadi, Phumla, et al.
Publicado: (2020)

KAF156 Is an Antimalarial Clinical Candidate with Potential for Use in Prophylaxis, Treatment, and Prevention of Disease Transmission
por: Kuhen, Kelli L., et al.
Publicado: (2014)

Interference with Hemozoin Formation Represents an Important Mechanism of Schistosomicidal Action of Antimalarial Quinoline Methanols
por: Corrêa Soares, Juliana B. R., et al.
Publicado: (2009)

Rapid and quantitative antimalarial drug efficacy testing via the magneto-optical detection of hemozoin
por: Molnár, Petra, et al.
Publicado: (2020)

Genetic validation of PfFKBP35 as an antimalarial drug target
por: Thommen, Basil T, et al.
Publicado: (2023)

Evaluation of a multiphasic parasite clearance profile after treatment of experimental human infection with the investigational anti-malarial M5717 using segmented mixed effect models
por: Yin, Xiaoyan, et al.
Publicado: (2023)

New In Vitro Interaction-Parasite Reduction Ratio Assay for Early Derisk in Clinical Development of Antimalarial Combinations
por: Wicha, Sebastian G., et al.
Publicado: (2022)

Absence of association between pyronaridine in vitro responses and polymorphisms in genes involved in quinoline resistance in Plasmodium falciparum
por: Pradines, Bruno, et al.
Publicado: (2010)

Etymologia: Hemozoin
Publicado: (2016)

Propensity of selecting mutant parasites for the antimalarial drug cabamiquine
por: Stadler, Eva, et al.
Publicado: (2023)

Population Pharmacokinetics of Tafenoquine, a Novel Antimalarial
por: Thakkar, Nilay, et al.
Publicado: (2018)

Author Correction: Propensity of selecting mutant parasites for the antimalarial drug cabamiquine
por: Stadler, Eva, et al.
Publicado: (2023)

Superparamagnetic Properties of Hemozoin
por: Inyushin, M., et al.
Publicado: (2016)

A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers
por: McCarthy, James S., et al.
Publicado: (2019)

Phospholipid Membrane-Mediated Hemozoin Formation: The Effects of Physical Properties and Evidence of Membrane Surrounding Hemozoin
por: Huy, Nguyen Tien, et al.
Publicado: (2013)

Target-Mediated Brain Tissue Binding for Small Molecule Inhibitors of Heat Shock Protein 90
por: Badolo, Lassina, et al.
Publicado: (2020)

Hemozoin‐induced activation of human monocytes toward M2‐like phenotype is partially reversed by antimalarial drugs—chloroquine and artemisinin
por: Bobade, Deepali, et al.
Publicado: (2018)

Defining the Antimalarial Activity of Cipargamin in Healthy Volunteers Experimentally Infected with Blood-Stage Plasmodium falciparum
por: McCarthy, James S., et al.
Publicado: (2021)

Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development
por: McCarthy, James S., et al.
Publicado: (2016)

Predicting Optimal Antimalarial Drug Combinations from a Standardized Plasmodium falciparum Humanized Mouse Model
por: Demarta-Gatsi, Claudia, et al.
Publicado: (2023)

Novel MenA Inhibitors Are Bactericidal against Mycobacterium tuberculosis and Synergize with Electron Transport Chain Inhibitors
por: Berube, Bryan J., et al.
Publicado: (2019)

Quantification of the antimalarial drug pyronaridine in whole blood using LC–MS/MS — Increased sensitivity resulting from reduced non-specific binding
por: Blessborn, Daniel, et al.
Publicado: (2017)

Hemozoin Inhibition and Control of Clinical Malaria
por: Ihekwereme, Chibueze Peter, et al.
Publicado: (2014)

Induction of Neuroinflammation and Neurotoxicity by Synthetic Hemozoin
por: Velagapudi, Ravikanth, et al.
Publicado: (2019)

Structure-Guided Identification of Resistance Breaking Antimalarial N‑Myristoyltransferase Inhibitors
por: Schlott, Anja C., et al.
Publicado: (2019)

Pharmacokinetic Interaction between Pyronaridine-Artesunate and Metoprolol
por: Morris, Carrie A., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_brn20jjuel2ohr169fhonk96ph